DBV Technologies S.A. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how DBV Technologies performed this year. My goal is to turn complex filing information into clear insights so you can decide if this company fits your investment strategy.

1. What does the company do?

DBV Technologies is a biotech company in the research phase. They do not sell products yet. Their main project is the Viaskin Peanut patch. This patch uses a special technology to deliver tiny doses of peanut protein through the skin. The goal is to train the immune system to tolerate allergens without the protein entering the bloodstream.

This year was about preparation. The company focused on the VITESSE Phase 3 clinical trial and the complex manufacturing needed to bring their patch to market. They successfully finished enrolling patients for the VITESSE trial. This is a vital step toward gathering the safety data required for FDA approval.

2. Financial performance

Because they have no products on the market, they have no sales revenue. For the year ending December 31, 2025, the company reported a $145 million loss. They spend about $10–$12 million each month. Over 75% of their spending goes toward research and development, specifically the VITESSE trial and their French manufacturing facility. Simply put: the company runs on investor cash, not sales. They must raise more money to keep operating through 2026.

3. Major wins and challenges

The company has a clear roadmap for 2026. They plan to ask the FDA to approve the Viaskin Peanut patch for children aged 4–7 in the first half of 2026. They hope to follow this with a request for the 1–3 age group later that year.

The challenge is that they are building their business from scratch. They lack a sales force and marketing team. They plan to target 4,500 U.S. allergists and 60,000 pediatricians, but they must build this entire operation before earning a single dollar. They also need to convince insurance companies to cover the product, which is essential for patient access.

4. Financial health

The company stays afloat by selling more shares. As of March 2026, they had about 296 million shares outstanding. They have no major long-term debt, but they rely entirely on investor confidence. They started 2026 with about $110 million in cash. If they miss their development goals, they could face trouble. They likely need another $150–$200 million to reach a point where they can pay for themselves.

5. Key risks

Biotech is high-stakes. Here is what could go wrong:

• Regulatory Hurdles: If the FDA demands more costly trials, the company’s timeline and value will suffer.
• Execution Risk: If they cannot reach doctors or secure insurance coverage, they won't make money even with an approved product.
• Dilution: Because they sell new shares to raise cash, your ownership percentage will shrink. Expect further share sales that could reduce your stake by 15–25% annually.
• Safety: Any unexpected side effects in their trials could halt progress and jeopardize FDA approval.

Final Thought for Investors: DBV Technologies is a "binary" investment. If the Viaskin Peanut patch receives FDA approval and successfully reaches the market, the company has a clear path to growth. However, because they are currently burning cash without revenue, they are entirely dependent on their ability to raise more capital. Before investing, consider if you are comfortable with the high likelihood of share dilution and the significant regulatory hurdles that remain in 2026.